[1]丛子涵 张明 吴奇勇**.以CYP2C19基因多态性为导向的双抗治疗方案在冠状动脉旁路移植术后的应用价值[J].中国微创外科杂志,2023,01(6):442-448.
　Cong Zihan,Zhang Ming,Wu Qiyong..Application Value of CYP2C19 Gene Polymorphismoriented Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting[J].Chinese Journal of Minimally Invasive Surgery,2023,01(6):442-448.
点击复制

以CYP2C19基因多态性为导向的双抗治疗方案在冠状动脉旁路移植术后的应用价值()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2023年6期
页码:
442-448
栏目:
临床研究
出版日期:
2023-06-25

文章信息/Info

Title:
Application Value of CYP2C19 Gene Polymorphismoriented Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
作者:
丛子涵 张明 吴奇勇**
(江苏省常州市第二人民医院心胸外科,常州213000)
Author(s):
Cong Zihan;  Zhang Ming;  Wu Qiyong.
Depatment of Cardiothoracic Surgery, Changzhou Second People’s Hospital, Changzhou 213000, China
关键词:
冠状动脉旁路移植术; 氯吡格雷; 替格瑞洛; CYP2C19基因; 主要不良心血管事件
Keywords:
Coronary artery bypass grafting; Clopidogrel; Ticagrelor; CYP2C19 gene; Major adverse cardiovascular events
文献标志码:
A
摘要:
目的探讨CYP2C19基因多态性检测指导冠状动脉旁路移植术(coronary artery bypass grafting，CABG)后双抗治疗方案的应用价值。方法回顾性分析2015年2月~2022年2月我院166例冠心病行CABG的临床资料，根据患者是否行CYP2C19基因检测及个体化抗血小板，分为个体化治疗组和常规治疗组，前者根据CYP2C19基因检测结果采用阿司匹林联合氯吡格雷或替格瑞洛治疗，后者采用阿司匹林联合标准剂量的氯吡格雷治疗。比较2组主要不良心血管事件(major adverse cardiovascular events，MACE)、出血事件发生情况，以及术后12个月桥血管通畅情况。结果个体化治疗组和常规治疗组患者MACE发生率分别为2.5%(2/80)、10.5%(9/86)，差异有统计学意义(χ2=4.250，P=0.039)；出血事件发生率分别为16.3%（13/80）、5.8%（5/86），差异有统计学意义(χ2=4.669，P=0.031)。术后1年冠状动脉CTA示个体化治疗组桥血管总体通畅率937%(252/269)，显著高于常规治疗组85.1%(239/281)(Z=-3259，P=0001)。结论基于CYP2C19基因指导下个体化抗血小板治疗方案，可以降低CABG患者术后MACE发生率，提高术后1年桥血管通畅率。
Abstract:
ObjectiveTo investigate the value of CYP2C19 gene polymorphism detection in guiding dual antiplatelet therapy of coronary artery disease after coronary artery bypass grafting (CABG). MethodsClinical data of 166 patients with coronary heart disease receiving CABG in our hospital from February 2015 to February 2022 were retrospectively analyzed. According to whether CYP2C19 gene detection and individualized antiplatelet therapy, they were divided into individualized treatment group and routine treatment group. The former was treated with aspirin combined with clopidogrel or ticagrelor based on CYP2C19 gene test results, and the latter with aspirin combined with a standard dose of clopidogrel. The occurrence of major adverse cardiovascular events (MACE), bleeding events, and bridging artery patency at 12 months after surgery were compared between the two groups.ResultsThe incidence of MACE in the two groups was 2.5%(2/80) and 10.5%(9/86), respectively, and the difference was statistically significant (χ2=4.250, P=0.039). There was a statistically significant difference in the incidence of bleeding (χ2=4.669, P=0031). Coronary artery CTA showed that the overall patency rate of bridging vessels in the individualized treatment group was 93.7% (252/269), significantly higher than that in the conventional treatment group 85.1%(239/281, Z=-3259, P=0001). ConclusionIndividualized antiplatelet therapy guided by CYP2C19 gene detection can reduce the incidence of postoperative MACE in patients after CABG and improve the bridging patency rate at 1 year after surgery.

参考文献/References:

[1]Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation,2015,131(10):927-964.
[2]Writing Committee Members, Lawton JS, TamisHolland JE, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol,2022,79(2):e21-e129.
[3]Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol,2018,72(23 Pt A):2915-2931.
[4]Lee CR, Luzum JA, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther,2022,112(5):959-967.
[5]顾畅,张杨杨.术中即时血流测定在冠状动脉旁路移植术中的应用进展.中国胸心血管外科临床杂志,2016,23(4):395-398.
[6]Quan Z, Zhang X, Song X, et al. The use of intraoperative transit time flow measurement can reduce postoperative myocardial injury. J Card Surg,2022,37(12):4246-4253.
[7]黄杰,于婷,张喆,等.CYP2C19基因多态性检测方法的建立.药物分析杂志,2015,35(9):1562-1567.
[8]Brouwer JMJL, Nijenhuis M, Soree B, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the genedrug interaction between CYP2C19 and CYP2D6 and SSRIs. Eur J Hum Genet,2022,30(10):1114-1120.
[9]朱刚明,谭源满,陶娟,等.基于深度学习的冠状动脉CTA人工智能后处理对疑似冠心病患者诊断价值的初步研究.临床放射学杂志,2021,40(11):2128-2133.
[10]Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.Circulation,2011,123(23):2736-2747.
[11]周衍再,朱云鹏,赵强.冠状动脉旁路移植术后桥血管病变的发生机制及其影响因素.上海医学,2021,44(12):939-944.
[12]赵强,郑哲.中国冠状动脉旁路移植术后二级预防专家共识(2016 版).中华胸心血管外科杂志,2016,32(10):577-583.
[13]Floyd CN，Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther,2014,141(1)：69-78.
[14]Sandner S, Redfors B, Angiolillo DJ, et al. Association of dual antiplatelet therapy with ticagrelor with vein graft failure after coronary artery bypass graft surgery: A systematic review and metaanalysis.JAMA,2022,328(6):554-562.
[15]柯略森,单飞,彭晓鹏,等.不同抗血小板治疗方案对冠脉搭桥术后桥血管远期通畅率的影响.中西医结合心血管病电子杂志,2020,8(25):67-68.
[16]Zhu Y, Zhao Q. Antiplatelet therapy after coronary artery bypass graftingreply. JAMA,2018,320(10):1036-1037.
[17]Pereira NL, Rihal CS, So DYF, et al. Clopidogrel Pharmacogenetics. Circ Cardiovasc Interv,2019,12(4):e007811.
[18]Backman JD, O′Connell JR, Tanner K, et al. Genomewide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. Pharmacogenet Genomics,2017,27(4):159-163.
[19]Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet,2010,376(9749):1320-1328.
[20]Goto S, Huang CH, Park SJ，et al. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndromerandomized, doubleblind, phase Ⅲ PHILO study. Circ J,2015,79(11):2452-2460.
[21]黄婧,韩小年,王金萍,等.替格瑞洛相关不良反应分析.中国药物应用与监测,2021,18(3):185-188.
[22]韩雅玲.替格瑞洛临床应用中国专家共识.中华心血管病杂志,2016,44(2):112-120.
[23]Ozawa T, Suda M, Ikegami R, et al. Dual antiplatelet therapy guided by CYP2C19 polymorphisms after implantation of secondgeneration drugeluting stents for management of acute coronary syndrome. Int Heart J,2018,59(1):21-26.

备注/Memo

备注/Memo:
基金项目：常州市科学技术局2020年基金(CE20205047)**通讯作者，Email:wqyxycxy@aliyun.com
更新日期/Last Update: 2023-09-07